Epigenetix

Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate cancer, pancreatic cancer, breast cancer, sarcoma, NUT carcinoma and other cancers where our drug has shown unprecedented anti-cancer activity. Our drug was selected among many other drug candidates to potently inhibit three different validated cancer drug targets: p300/CBP + BRD4+ CECR2. Treatment results in elimination of both the tumor itself as well as associated metastases. This powerful drug fights cancer in multiple ways:(1) by eradicating tumor cells directly (cytotoxic therapy),(2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). While presently pursued as monotherapy, synergy with checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors as well as epigenetic drugs, such as EZH2 inhibitors,has been shown preclinically.